Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Biol Chem ; 292(28): 11829-11839, 2017 07 14.
Article in English | MEDLINE | ID: mdl-28559277

ABSTRACT

There is significant clinical need for new antifungal agents to manage infections with pathogenic species such as Cryptococcus neoformans Because the purine biosynthesis pathway is essential for many metabolic processes, such as synthesis of DNA and RNA and energy generation, it may represent a potential target for developing new antifungals. Within this pathway, the bifunctional enzyme adenylosuccinate (ADS) lyase plays a role in the formation of the key intermediates inosine monophosphate and AMP involved in the synthesis of ATP and GTP, prompting us to investigate ADS lyase in C. neoformans. Here, we report that ADE13 encodes ADS lyase in C. neoformans. We found that an ade13Δ mutant is an adenine auxotroph and is unable to successfully cause infections in a murine model of virulence. Plate assays revealed that production of a number of virulence factors essential for dissemination and survival of C. neoformans in a host environment was compromised even with the addition of exogenous adenine. Purified recombinant C. neoformans ADS lyase shows catalytic activity similar to its human counterpart, and its crystal structure, the first fungal ADS lyase structure determined, shows a high degree of structural similarity to that of human ADS lyase. Two potentially important amino acid differences are identified in the C. neoformans crystal structure, in particular a threonine residue that may serve as an additional point of binding for a fungal enzyme-specific inhibitor. Besides serving as an antimicrobial target, C. neoformans ADS lyase inhibitors may also serve as potential therapeutics for metabolic disease; rather than disrupt ADS lyase, compounds that improve the stability the enzyme may be used to treat ADS lyase deficiency disease.


Subject(s)
Adenylosuccinate Lyase/antagonists & inhibitors , Antifungal Agents/pharmacology , Cryptococcus neoformans/enzymology , Drug Design , Enzyme Inhibitors/pharmacology , Fungal Proteins/antagonists & inhibitors , Models, Molecular , Adenylosuccinate Lyase/chemistry , Adenylosuccinate Lyase/genetics , Adenylosuccinate Lyase/metabolism , Amino Acid Sequence , Animals , Antifungal Agents/chemistry , Antifungal Agents/therapeutic use , Binding Sites , Cryptococcosis/drug therapy , Cryptococcosis/metabolism , Cryptococcosis/microbiology , Cryptococcus neoformans/drug effects , Cryptococcus neoformans/genetics , Cryptococcus neoformans/pathogenicity , Crystallography, X-Ray , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/therapeutic use , Female , Fungal Proteins/chemistry , Fungal Proteins/genetics , Fungal Proteins/metabolism , Gene Deletion , Mice, Inbred BALB C , Molecular Conformation , Protein Conformation , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/metabolism , Sequence Alignment , Structural Homology, Protein , Survival Analysis , Virulence/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...